intra aortic balloon pump (IABP) underscore Datascope's leadership
position in the Cardiac Assist market. The state-of-the-art Sensation 7
Fr. eliminates conventional blood pressure monitoring and enables
clinicians to deliver counterpulsation therapy to a broad array of
patients, including those with smaller peripheral blood vessels. The
automatic CS300 pump is the most advanced of its kind and sets a higher
standard of care for patients who require balloon support.
In addition, over the last year alone, Datascope has introduced nine new
products that address market opportunities, including: Spectrum OR, Gas
Module SE-Sprirometry, SpO2 Telepak and new software products that
increase the functionality of our Panorama central monitoring system.
- Continued investment in Research & Development. Investment in R&D is
critical to Datascope's continued growth and success. Over the last
four years, Datascope has invested a significant portion of our R&D
resources in developing NetGuard. We are committed to continuing to
invest in R&D and have a number of exciting new products in the pipeline.
- Focusing on growing our core businesses. In October 2006, after thorough
analysis, your Board and senior management determined to exit the
interventional products market. As a result, the Proguide IPD assets
have been sold and the Company is in discussions to divest other IPD
assets. Datascope's plan to exit the IPD business has led to
approximately $17 million in annual cost savings.
We also established Datascope Japan K.K. as a wholly-owned subsidiary to
manage our IABP business in Japan. With this new subsidiary, we have the
opportunity to expand our business presence in Japan, the world's second
largest market for medical devices.
- Making strategic acq
|SOURCE Datascope Corp.|
Copyright©2007 PR Newswire.
All rights reserved